University of Rhode Island

DigitalCommons@URI
Open Access Master's Theses
1994

FORMULATION OF AN ORAL MODIFIED RELEASEDOSAGE FORM
OF AN ADRENERGIC DRUG
Suresh Palaniswamy
University of Rhode Island

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
Palaniswamy, Suresh, "FORMULATION OF AN ORAL MODIFIED RELEASEDOSAGE FORM OF AN
ADRENERGIC DRUG" (1994). Open Access Master's Theses. Paper 278.
https://digitalcommons.uri.edu/theses/278

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information,
please contact digitalcommons@etal.uri.edu.

I"

FORMULATION OF AN ORAL MODIFIED RELEASE
DOSAGE FORM OF AN ADRENERGIC DRUG

BY
'

SURESH PALANISWAMY

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE .
REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN
PHARMACEUTICS

UNIVERSI'IY OF RHODE ISLAND
'·

1994

(

,.i.

MASTER OF SCIENCE THESIS
OF
SURESH PALANISWAMY

APPROVED:

Thesis committee
Maj or professor
(

UNIVERSI1Y OF RHODE ISLAND

1994

ABSTRACT
Albuterol, a sympathomimetic amine is a potent selective Beta
adrenergic agonist. As a result it is used as a bronchodilator to treat
chronic obstructive airway diseases in adults and childrens. The drug
has a short half-life of 3-4 hours and must be administered 3-4 times
daily to maintain a therapeutic concentration.
This investigation was undertaken to study the in-vitro drug
release characteristics of the marketed product under conditions that
mimic in-vivo dissolution behavior. It was determined that the original
marketed product released the initial dose in first half an hour and then
the second dose after a period of 5-6 hours. High variability in drug
release profiles were observed between various lots. It was decided to
investigate the applicability of several new polymers and modern
formulation techniques to provide similar but more reproducible release.
To reproduce the extended release portion of the tablets, various
concentrations of polymer and tabletting excipients were evaluated and
an optimum formulation that provided near zero order release was
determined. The formulation developed in the laboratory was scaled up
to a production size batch. Various physical characteristics of the tablets
were evaluated as specified in the USP XXII.
Two different types of coating processes, the Accela-cota and
fluidized bed coating apparatus (Aeromatic STREA I). were used to coat
the tablets with an aqueous polymer latex dispersion to retard drug
release from tablet cores for a period of 5-6 hours. These tablets were
further coated with 2 mg of albuterol per tablet to provide the immediate

ii

release dose. Optimum coating parameters were determined for the seal
coating and the immediate release coating.
A

High

Performance

Liquid

Chromatography

and

UV

spectrophotometric assay method were used to determine drug release
from the dissolution samples. The USP Apparatus I (Basket) and III
(Reciprocating cylinder) dissolution testing methods were used for
evaluating drug release from the marketed and the developed products. A
statistical evaluation using ANOVA was performed on all the dissolution
tests to compare the difference in mean drug release between different
batches of the developed product and the marketed product. A significant
difference in mean drug release was observed between different lots of
tablets at various time points in the marketed product. The in-vitro
dissolution data shows that the drug release profile of the developed
product is less variable than the marketed product.
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I INTRODUCTION

(

Over the past three decades, significant advances have been
made in the development of

new and improved drug delivery

systemst. Due to the modern technology, processing methods, and the
availability of variety of polymers, oral drug delivery systems are now
able to achieve predictable and reproducible release rates for an
extended period of time2. Greater utilization of controlled release drug
delivery has been possible due to various factors such as the discovery
of novel polymers, a better understanding of formulations, the
expiration of existing patents, the high cost of developing new drug
entities, improvement in processing technology and the elimination of
organic solvents that cause environmental and health hazards3.
Controlled-release delivery systems are designed to meet a
specific biopharmaceutical requirement of an active drug producing
(

steady-state plasma drug levels for a prolonged time4. Drugs suitable
for inclusion into modified release drug delivery systems usually have a
short half life or a narrow therapeutic index. Another aspect to
consider is the significant improvement in patient compliance often
seen with these products during the therapy3.

Conversely,

conventional solid dosage forms often lead to fluctuations in plasma
levels that may exceed the maximum and minimum therapeutic levels
as well as requiring multiple dosing intervals that lead to reduced
patient compliance.
Albuterol, a sympathomimetic amine derivative of .B-phenyl
ethylamine, is a potent selective .B-adrenergic agonist with less Beta 1
adrenergic activity, and preferential Beta2 adrenergic activity that
provides bronchodilation with little myocardial stimulation5. As a

1

result, it is used as a bronchodilator to treat chronic obstructive

(

airwaydiseases in adults and children. Albuterol may be administered
in a variety of dosage forms. Albuterol is available on the market in the
form of albuterol sulfate syrup, and tablets for oral administration, also
in the form of albuterol for oral inhalation. The tablets are available as
2 mg and 4 mg conventional release and 4 mg repeat action tablets.
The repeat action tablets were designed to deliver 2 mg immediately
which is coated on the outer most layer

and 2 mg slowly from the

core for a period of several hours5. The oral inhalation dosage form
provides a metered dose of 90 µg of albuterol for each actuation. The
only controlled release oral dosage form of albuterol in the US market
is Proventil Repetabs and the market potential of this dosage form is
significant.
Albuterol is readily absorbed from the GI tract. Initial activity
occurs within 15 minutes and lasts for a period of 4-5 hours. The drug
is excreted in urine in about 24 hours and about 50 % of the orally
administered drug is excreted within 3-4 hours . Maximum plasma
albuterol concentration of about 18 ng/ml are achived within 2 hours
after administration of 4 mg as syrup5. The peak plasma concentration
of albuterol and the metabolites are reported as 5 . 1-11 . 7 µg percent at
2.5 to 3 hours after an oral dose of 4 mgs.s.
Albuterol is metabolized to a polar metabolite in humans, which
has spectral and chemical properties different from the parent drug.
Albuterol is contraindicated in patients with cardiovascular disorders.
Teratogenic effects have been reported for albuterol in animals and
oral administration of the drug has been shown to delay pre term
labor6.B.

2

However, owing to a short-half life of 3-5 hours the drug must be
(

administered

3-4

times

daily

to

maintain

a

therapeutic

concentration5,6. Unfortunately, this requires careful observance of the
treatment regimen which ultimately interferes with the ability to
achieve full therapeutic benefit from the treatment. The main
objective of a modified release dosage form development is to reduce
the number of doses from four to two per day.
An extended release formulation of albuterol is marketed but the

detailed technology is not reported. However first marketed in the
1950's using old technology, there has been no further modifications
in the design and processing methods of these dosage forms. Contents
as reported in the labeling of the marketed products of this type show
use of excipients that are

derived from natural origin. These

excipients show variability in content, drug release and often give less
than reproducible results.
Excipients obtained from natural origin is difficult to process
and often prone to microbial contamination which in turn requires
strict quality control testing before processing into a dosage form.
Organic solvents used in processing this materials are often hazardous.
The recovery of these solvents also adds to the manufacturing cost.
This investigation was undertaken to study the in-vitro drug
release of the marketed product under conditions that mimic the invivo process; and then to develop a new modified release dosage form
with consistent drug release based on the combined polymer matrix
and aqueous coating technology. This approach eliminates the use of
organic solvents and uses an aqueous coating to retard drug release
from the core for several hours after the first dose is released from the

3
•

outermost
(

layer.

This

method

increases

the

efficiency

of

manufacturing and decreases variability by eliminating the use of
excipients obtained from the natural origin. Thereby giving a cost
effective product which is advantageous in this era of cost reduced
health care.

4
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1. Physicochemical Properties of Albuterol

HO

2
Molecular Weight:

239.31

Chemical name

N-tert-butyl-2-(4-hydroxy-3-hydroxymethyl
phenyl)-2-hydroxyl amine.

Generic names

Albuterol. Salbutamol

Appearance

White crystalline powder odorless and
tasteless

Melting point

151-152°C

Solubility

1 in 70 of water
1 in 25 of ethanol

pKa

9.3 and 10.3

UV Absorbance

Maxima at 226 and 276

Therapeutic
Category

Sympathomimetic amine used as a
bronchodilator

Precautions

Stored in a light resistant container.

5

2. Controlled Release Dosage Forms
(

The term "Controlled release" has become associated with those
systems from which therapeutic agents may be automatically delivered
at a predetermined rate over a long period of time9. Products of this
type have been formulated for oral, injectable, topical use and also
include inserts for placement into body cavities9, IO.
In general, controlled release delivery attempts to9:
1. Sustain drug action at a predetermined rate by maintaining a
relatively constant, effective drug level in the body with concomitant
minimization of the undesirable side effects often associated with the
saw tooth plasma levels of single repeated dosage forms.
2. Localize drug action by spatial placement of the controlled release
dosage form adjacent to or in the diseased tissue or organ.
3. Target drug action by using carriers or chemical derivatization to
deliver drugs to a particular "target" cell type.
In practice, a very few if any of the applied systems embrace all
of these activities. For the most part, these products focus on
maintaining a constant drug level in the plasma. Theoretically, in a
controlled release system, the rate of absorption should equal the rate
of elimination. However, this is possible only by the use of an
intravenous infusion. Thus, in practice alternative noninvasive routes
such as oral, nasal and transdermal routes are preferred in attaining
the therapeutic objectives of controlled release.

2.1. Oral Controlled Release Systems

Oral controlled release systems are popular because of
convenient administration and reduced design constraintsB. Ideally,

6

an oral controlled release preparation should immediately provide part
of the dose at the absorption site to achieve a rapid therapeutic
response. The remaining drug should be available at a rate sufficient to
maintain the desired pharmacological activity9.
The Design of an oral controlled release system is subject to a
number of variables among these are the location of the target site
which maximizes

absorption, the physicochemical properties of the

drug, the desired dose and extent of therapy, disease and patient
variables.
Over the past five decades a number of technologies have been
developed and employed to sustain the delivery of oral medications to
the systemic circulation. These systems are largely based on the
principles of diffusion, dissolution. ion exchange and recently on the
principle of osmosis (GITS). A variety of methods have been used to
retard drug release. The following is the summary of the methods
given by Lee et al9.

1. Capsules of polymeric material filled with a solid or liquid drug or
with a suspension of drug in a fluid, such that drug release is
controlled by diffusion through the capsule wall
2. A heterogeneous dispersion of drug particles in a solid matrix
which can be either biodegradable or non biodegradable and which
controls drug release by diffusion through the matrix, by erosion of the
matrix, or by a combination of both diffusion and erosion
3. A laminate of therapeutic agent and polymeric material made by
coating a film of biodegradable or non biodegradable material with
solid drug and then

forming the film into

7

a sealed "sandwich" or

'jelly roll", in which drug release is by diffusion
4. A heterogeneous dispersion or solution of drug in a water swellable
hydrogel matrix, which controls drug release by slow surface-to-center
swelling of the matrix by water and subsequently diffusion of the drug
from the water-swollen part of the matrix
5. Liquid-liquid encapsulation of drug in a viscous solution of polymer,
which controls drug release by slow diffusion via dilution of the media
6. Pumps that either mechanically or chemically (osmotic pressure)
provide drug in a controlled manner
7. Drug coated micropellets which have an apparent density lower
than that of the gastric juice. Thus, the final product floats in gastric
juice and remains in the stomach for an extended period, while slowly
releasing drug
8. Drug-containing bioadhesive polymer that adheres to the mucin
coating of the gastrointestinal tract and which is retained on the
surface epithelium to extend GI transit time of the drug. Drug is
released at a controlled rate from the bioadhesive polymer for
subsequent absorption
9. Chemical bonding of a drug to a polymer backbone by pendent
amide or ester linkages in which hydrolysis controls drug release.
10. Formation of macromolecular structures of the drug via ionic or
covalent linkages, which controls drug release by hydrolysis,
thermodynamic dissociation, or microbial degradation

2.2. Diffusion Controlled Release

Drug release is controlled by a combination of several physical
processes such as penetration of water, leaching of drug from the

8

matrix, and erosion of matrix material. Alternatively, drug is dissolved
in the matrix material and released by diffusion through the matrix
material. In this latter case, the drug release is controlled by
dissolution and diffusion. These type of dosage forms are the simplest
to prepare. They are usually prepared by dispersing the drug particles
in a polymeric matrix or by coating the drug particles or the granules
with varying thickness of a retardant polymeric material. The basic
principle of drug release from a polymer matrix is as follows: The drug
dissolves in the polymer matrix and diffuses out from the surface of
the matrix. As the drug is released, the distance for diffusion of the
drug from the marix to the saturated solution increases. The drug is
leached out from the interconnecting pores and or capillaries. The
release kinetics of such dosage forms are given by Higuchi9.

dmt/dt

=A/2

(2DCsCo/t)

112

Where A is the area, D is the diffusion coeffecient, Cs is the solubility
of active drug in the matrix, Co is the total concentration in the matrix
mt is the total amount of drug released at time t.

2.2.1. Repeat Action Tablets

A repeat-action tablet is one that provides the usual single dose
of the drug immediately after administration and delivers the next
single dose after a period of time. Repeat-action tablets are not true
sustained release products. However, the dosage form is designed to
extend the activity of the second dose of the drug often after the effect
of the first dose has diminished. In this type of dosage forms the core

9

serves as the base to which the initial dose is applied by usual coating

(

techniques.
This type of dosage forms is prepared either by coating the
immediate release portion of the drug over

an enteric coated core

tablet or by presscoating the initial dose over the core which has been
coated with an enteric material. Figure 1. shows the schematic
representation of dissolution process of a repeat-action tablets.

2.2.2. Albuterol Extended Release Tablets

Albuterol sulfate has been studied extensively and formulated
into various types of dosage formsio.11.12,13. To date, the only
controlled release oral dosage form available in the US market is
albuterol sulfate repetabs7. The other oral dosage forms available in the
market are conventional tablets, syrups and oral inhalations. These
dosage forms are designed to deliver two or four mg orally or 90 µg
per actuation for inhalation in a metered dose 7.

3. General Aspects of Coating

The process and techniques employed in the coating of tablets
were inherited from the pill coating technique 15 and have been
surrounded by secrecy. Tablet coating is a unit operation in which a
layer of designed thickness of a suitable material sugar or film is cast
around a compressed tablet core 13.
There are a number of various reasons for coating tabletsl3,14:
1. Improve the appearance of the tablet

2. Mask the odor and taste of the drug in the core
3. Protect the drug from its surrounding environment (air, light, and
\
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Repeat-action Tablets
(

Dissolution Of
Immediate Release Portion

Seal or Enteric
Coat

Intact Core Containing Second Dose

-----)

Diffusion And Erosion
Controlled Release
Slowly Dissolving and Eroding Core

Figure 1. Design And Mode Of Drug Release From a
Repeat-action Tablet
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DRUG IN
SOLUTION

moisture) and improve stability
(

4. Program the release of the medicament at a certain rate over a
given period of time
5. Improve the product mechanical integrity
6 . Reduce or eliminate incompatibility of two or more drugs
7. Improve the product identity from manufacturing to patient

3.1. Sugar Coating

In the recent past sugar was the most widely used material for
coating tablets 15,1 s . 1 7. Gelatin and sugar are used as main coating
materials since they are readily soluble and proven safe for domestic
use 15. Sugar coating is essentially a multiple process where success is
still measured in terms of the elegance of the final product. This type
of coating is still largely dependent on the use of skilled manpower.
The basic procedure of sugar coating can be broken into four
distinct operations. Sealing, subcoating, smoothing, coloring and
polishing. While a detailed description of this topic is out of scope of
this thesis. Figure 2. briefly illustrates the various steps involved in the
sugar coating process 1 7 . A seal coat is applied to the tablet core to
prevent the moisture penetration, usually employing a sealant such as
shellac. Subcoating or the foundation is applied to round out the sharp
edges and build up the tablets to a desired size and shape. Smoothing
is achieved by applying several coats of plain syrup . When the tablets
become perfectly smooth, a subsequent syrup coating that contains a
suitable color is applied. Finally the tablets are polished in a canvaslined pan to give the desired luster.

12

(

Sealing

J

(

Based on
initial core
weight,
50-lOOi
weight gain
achieved

Subcoating,
Grossing
& Smoothing

t
Color
Coating

+.
Polishing.

Figure 2. Steps Involved In the Sugar Coating Process for Tablets
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3.2. Film Coating

(

Utilization of some kind of coating process to modify the
characteristics of a dosage form has long been practiced in the
pharmaceutical industry. Film coating in the pharmaceutical industry
was introduced by Abbott laboratories with the first commercial film
coated product introduced into the market in 195317.
Film coating affords greater flexibility, faster processing time
and an overall increase in manufacturing efficiency. The process
involves deposition of a thin (20-150 µm), polymer-based coating
material onto the surface of a pharmaceutical substrate. The film
coating process is mainly accomplished by the spray application of
polymer solutions using volatile solvents. The film-forming process
involves two major steps, deposition of the polymer particles as fine
droplets onto the tablet surface and coalescence of the droplets to

(

form a thin film which is accompanied by continuous drying. Figure 3.
shows a schematic representation of the film coating process.
The quality of film coating is influenced by the formulation and
the process used. Several formulation and manufacturing problems are
related to coating formulations 18. The viscosity of this coating liquid
influences delivery, atomization and spreading of the polymer solution.
Poor uniformity in film thickness, results from uneven spraying of the
film forming polymer. Drug release properties from the core may be
altered due to porosity or thickness of the polymer film20.21.

3.2.1. Film Coating Materials

Since its introduction in the 1950's, film coating has undergone
some radical change, both with respect to the equipment used for

(
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Figure 3. Schematic Representation of Film Coating Processes

processing and coating formulations used23,24. The major change, of
course is represented by the transition from non-aqueous film coating
to aqueous film coating. If we follow the progress of pharmaceutical
coating technology, we will see that it has essentially gone full circle.
Figure 4. shows the evolution of the film coating processes. The
coating process that began predominantly with the use of water based
suspensions to provide sugar coating ultimately became essentially non
aqueous to provide polymer ftlms.

Initially film coating used organic

solvents due to the advantages of shorter processing time and reduced
effect of heat and moisture on the stability of the drug. Finally the
trend has resulted in preference being shown for an aqueous
process25. This change has occurred as the result of a desire to
eliminate certain disadvantages associated with the use of organic
solvents. Namely the hazards concerned with using flammable
materials, concerns over the use of toxic materials, the environmental
issues surrounding atmospheric pollution by gaseous effluents used in
the coating process and lastly the continued increase in solvent cost.
Thus, aqueous film coating has become more acceptable and
produced major benefits with respect to safety and cost. One potential
drawback, however, when using aqueous coating is the relatively high
latent heat of vaporization of water26. Thus one should anticipate that
greater difficulty will be experienced in removing water from an
applied film coating than that found with the previously used organic
solvents. Concerns related to this issue are the potential for increased
processing time, greater risk of temperature and moisture affecting
drug stability, and opportunities for changes in drug release
characteristics27,2s. In order to minimize these concerns, aqueous

16
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Non-Aqueous Processes

Aqueous Processes

Sugar coating

(__J
Film Coating

[__J
Film Coating

Figure 4. Evolution Of Pharmaceutical Coating Processes
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coating solutions containing a higher percent of solids than found in

(

organic solvent based coating solutions are used27. This approach
minimizes both the total amount of coating solutions applied and thus
the amount of water that has to be removed. As a result, a compromise
has to be made between coating solid load, process time, product
stability and the desired release characteristics28.

3.2.2. Issues Related to Aqueous Film Coating

Aqueous film coating deals with two predominantly different
types of coating systems, namely: Solutions of polymers in water and
dispersions (latex) of polymers in water. Aqueous polymer solutions
are typically used when conventional water soluble coatings are
required29. While a latex dispersion is used to produce a more highly
functional film coating. When solutions of polymer in water are used,
the viscous liquid is converted into a viscoelastic solid during the ftlm
formation process. The various stages of this process are, rapid surface
evaporation of solvents which causes an increase in polymer
concentration and a decrease in the overall area from which the
solvent can evaporate. Continued loss of solvent, proceeds at a slower
rate largely determined by solvent diffusion through the polymer
matrix to the surface. "Solidification" of the film results from
immobilization of the polymer molecules. Continued solvent loss
continues

at an extremely low rate with concurrent formation of

shrinkage stresses within the film as a result of constraints imposed
by the immobility of polymer molecules and adhesion of coating to the
substrate. As solvent loss occurs, the glass transition temperature of
polymer/solvent mixture is continually raised, and free volume
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(intermolecular space) is diminished. Ultimately free volume may
(

decrease to such a low level that it is impossible to effectively remove
the last trace of solvent from the film28.
Formation of a film from an aqueous polymeric dispersion
follows a different and more complex procedure. In the liquid state,
the polymer is in the form of discrete particles dispersed in an
aqueous vehicle. To form a continuous film, these polymeric particles
must be consolidated, deformed, and ultimately fused together28,29.
The complexity of the film forming process with in latex
dispersions has given rise to several competing theories3o. Generally,
during film formation sufficient pressure must be developed to cause
the polymeric particles to deform and coalesce. This coalescence is
facilitated by the interparticulate capillary forces that are generated as
water evaporates. However complete coalescence can only occur as a
result of viscous flow which eliminates the boundaries between the
adjacent polymer particles. Thus "diffusion" of polymer chains across
the boundaries must occur which is possible only if sufficient free
volume exists in the bulk polymer to accommodate the diffusion
process. Thus the formation of these polymeric dispersion is critical
for successful film coating. Processing conditions such as spray rate,
atomizing air pressure, droplet size. droplet distribution, drying
conditions (air flow, temperature and humidity) spreading and
coalescence are equally important3 I.

3.3. Processing Equipment

The choice of proper equipment and creation of a suitable
processing environment is as essential to achieving a good film coating
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as selecting an appropriate coating formulation2 9 . This is particularly
true for aqueous film coating. Film coating requires a delicately
balanced environment. The coating material must contain sufficient
solvent to adhere properly and coalesce as it reaches the surface of the
substrate, yet it also must dry rapidly and not be transferred from one
tablet or particle to another. To create the necessary environment for
this process to occur, specialized coating equipment is required.

3.4. Coating Pan

Over the past several decades, the design of coating pans have
undergone major changes due to advances in coating technology and
an increased demand for compliance with GMP's3I. Originally,
pharmaceutical coating pans evolved from

designs

used in

confectionery pan coating. However, it was obvious that aqueous film
coating placed significant demand on the drying capabilities of the
coating equipment. Designers of such equipment have made a variety
of modifications to increase the interaction between the product being
coated and the air responsible for removing solvent from that product.
In this regard fluid-bed equipment is considered as most effective31.32.
However, in spite of the advantages of the fluid-bed coating
equipment, the so-called side vented pan has surfaced as the design of
choice in most film coating applications. While a multitude of side
vented pan designs exist, the basic principles are similar. The air is
introduced into the interior of the pan, drawn through the product
being coated, and exhausted to the exterior. Several of the approaches
to air flow in the various types of side vented pans are shown in Figure
5.
I

\

20

(

Style #l

St v le #2

1

inlet

1

inlet

2

outlet

2

outlet

Style i!J

St y le #4

1

= inlet
= L~let

1 = inlet

2

2 = outlet

3 = outlet

Style #5

Style #6

1 = inlet or outlet
1 = inlet

2 = inlet or

3

outlet
.. inlet or
outlet

2 = outlet

St v le

~7

1 = inlet

2 = inlet or outlet
3 = in let or outlet

Figure 5. Air Flow Patterns In Side Vented Pans
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or outlet
or outlet

3.4.1.A.ccela-cota
(

The Accela-cota equipment introduced in 1960's (by Thomas
Engineering), is based on a design patented by Eli Lilly who was the
pioneer in the design of side-vented pansIB. Equipment of this type
consists of a perforated drum that is rotated on its horizontal axis in
an enclosed housing. The coating solution is applied to the surface of
the rotating tablet bed via spray nozzles that are positioned within the
drum. Figure 6. shows a schematic representation of the Accela-cota.
This equipment has undergone various modifications since being
introduced. Air flow through the pan and the product is facilitated by
more fully perforating the cylindrical portion of the pan. Air is
introduced by a plenum in contact with the top of the pan and is
drawn through the pan and tablets. The air is then exhausted through
a plenum located on the exterior of the pan in a position immediately
below the cascading bed of tablets . The air flow pattern of Accela-cota
is similar to that shown in style # 1 of figure 5. There are various
alternative coating equipment available in the market include Hicoater, Dicoater and Glatt pan-coating equipment. All of those designs
differ slightly in air flow patterns and vent.

3.5. Fluid-bed Coating Equipment
The fluid-bed or air suspension process has long been used in
the coating of pharmaceutical solids. Equipment for this process was
originally patented in the 1950's by Wurster32 . A schematic diagram of
the Wurster fluid-bed coating process is shown in Figure 7.
During normal operation, fludizing air causes the product being
coated to accelerate rapidly up through the inner partition which
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Figure 6. Schematic Representation Of Accela-cota
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Figure 7. Schematic Representation Of Wurster Fluid-bed
Coating Process
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defines the spray zone. Deceleration occurs in the region of the top
expansion chamber, causing the product to drop back into the coating
(

chamber as confined by the walls of the chamber and the insert. The
product moves quickly down to the bottom of the coating chamber
where the cycle begins again. In the heyday of organic-solvent based
film coating, the wurster process proved to be very popular for coating
tablets33. The product coated in the wurster process is typically
characterized by uniform coating and the process itself exhibits
excellent drying characteristics. Since the aqueous process would
benefit from these outstanding drying capabilities, there is a growing
interest in this type of equipment for aqueous film coating of tablets33.
The Aeromatic fluid-bed coating equipment designs are versatile
which operate on the same principles as the wurster process. This
type of coating equipment has many added features and is designed to
accommodate a variety of modular inserts such as dryer, spray
granulator, aero-coater for bottom spray coating and ultra coater,
bottom/tangential spray for tablet coating. Since these film coatings
need to be highly functional, the benefits of the fluid-bed process, with
its capabilities for applying coating uniformly with minimized particle
agglomeration are readily evident and outweighs the side vented pan
coating equipment in this regard.

4. Methods For Testing Drug Release

Setting up a dissolution method for evaluation of drug release
during the development of a new dosage form is of critical
importance. It has

been well established that different operating

parameters of the various dissolution methods can yield different
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results40,4 I. In the compendia, stirring rate, volume and mesh may
vary for individual drug monographs. The USP further specifies special
(

criteria for monitoring the dissolution of controlled release dosage
forms and also recommends that drug release be monitored at various
pH's to mimic the in-vivo dissolution behavior.
A number of dissolution methods have been developed, but only
a few are officially recognized by the USP. The Tumbling method was
developed in 1930 followed by various methods such as Beaker
method, Rotating disc, Magnetic basket and Rotating bottle. The
rotating bottle was not the method of choice due to the limitations in
media volume and lack of automation4 I. The USP basket was
introduced in 1969 and USP paddle was introduced in 197842.

4.1 USP Apparatus I

The USP basket method or apparatus I is the primary in-vitro
dissolution testing equipment for conventional release dosage forms.
It was adopted as the first official method by the USP XVIII in 196943.

The basket apparatus described in USP XXII, is simple, robust and
adequately standardized because of this advantage it is recommended
by the USP for the in-vitro dissolution testing of controlled release
preparations. This apparatus consists of a 40 mesh, stainless steel
wire basket, 1000 ml capacity dissolution flask. A water bath which
maintains the temperature of the dissolution medium at 37°±0.5°C.
The basket is rotated at varying speeds from 25 to 150 RPM. However,
because of the 'single container' nature of the basket apparatus it is
difficult to change the test media partially during the test especially if
the dissolution of the drug should be studied in various pH. Thus the
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USP apparatus III (Reciprocating Cylinder) and apparatus IV (Flow
through cell) has distinct advantage over the basket apparatus
preferably for testing controlled release dosage forms. Figure 8.
shows the specification of the basket apparatus43.

4.2. USP Apparatus

In-vitro

m (Reciprocating Cylinder)

dissolution of a dosage form under appropriate

conditions allows the prediction of in-vivo behavior: this is true for
sustained and controlled release dosage forms which have to be
studied under various pH conditions and in the presence of media
resembling those likely to be present in the GI tract during the transit
of the dosage from.
When the USP apparatus I and II were recognized as official
instruments for in-vitro dissolution testing. Various researchers have
observed difficulties in using this instruments to evaluate controlled
release dosage forms44.45.46. Especially when the pH of the media has
to be changed and the sink conditions has to be maintained during the
dissolution process. For more than a decade there was no appropriate
dissolution testing apparatus suitable for testing

controlled release

preparations at various pH's, until the USP apparatus III, the
reciprocating cylinder and the flow through apparatus IV, was
recognized officially in 199315. 53.
Beckett et al48 proposed a novel device. the "Bio-Dis", that can
be automated, thereby saving handling time and can be used to
determine drug release at various pH's. Which is now recognized
officially as USP apparatus III (USP XXII supplement VI 1993) or the
reciprocating cylinder. This apparatus is recommended by USP for
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General
•

Water bath temperature 36 .5 ° C-37.5°C

•

Media as 1n monograph , but otherwise 900 ml 1n USP/
NF and 1000 ml 1n BP. BP specifies deaerat1on .USP / NF
states dissolved gasesmust not 1n te~fere

•

Samples required : USP / NF 6 + 6 + 1 2 sequenced until
spec1f1cat1on is met . BP 5 + 5 sequenced for 100% of

5
Speed (rpm) as specified in monograph
25- 150 rp m ( ± 4% USP / NF ± 5% BP)
Shaft
USP/NF - 6-10.5-mm diameter;
BP - approximately 6-mm diameter;
2-mm vent in drive disc
Centering (or tilt)
± 2 mm at all points

Eccentricity
USP/ NF - no significant wobble;
BP - no perceptible wobble

Sampling Point
USP/NF - midway from top of
basket to top of fluid and
no closer than 1 cm to
side of flask
BP - halfway between basket
and side at middle of basket
Flask
USP/NF - cylindrical
with spherical bottom ,
16-17.5-cm high , inside
diameter 10-10.5 cm, plastic
or glass
BP - cylindrical. flat
bottomed. glass
Basket

Basket Position
USP/NF - 2 .5
0 .2 cm
BP - 2 .0 ± 0 .2 cm

±

Figure 8. Specifications for USP Basket Apparatus I
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testing drug release from controlled release dosage forms. This

(

equipment has the advantage that the medium pH can be changed
with out interrupting the test. Figure 9. shows the specification of
reciprocating cylinder USP apparatus IJI53.
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(
Air holes
3.9 mm diameter

Splash cover
60.6 mm
I

lJ 1. IJ

: ! . . . . '- . . . -.:
...
- . . , .

Reciprocating
shaft
6.3 mm diameter

.138.1 mm

~

.-

------,

I
Air holes
3.9 mm diameter

180 mm
glass vessel

Glass
I' . / reciprocating
I Dosage I / .
cylinder
form
I
25 mm inside
I I diameter 100 mm long
I ~ I I
.

I

I

I

,,..h

I

I

I

I

Type 316 stainless
mesh screen
(top and bottom)

I
18mm

I•

'

46.8 mm

Figure 9. Specifications for USP Apparatus III (Reciprocating cylinder)
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II PURPOSE OF STUDY

Describing that number of products on the market for a long
period containing many natural ingredients which often show variability
in the content uniformity and drug release; Over the past years greater
number of new excipients introduced in pharmaceutical formulation,
which have specific components that are well defined, improved shelf-life
and cost effective processing techniques that are environmentally safe.
Hence it would be desirable to formulate a dosage form using the novel
technique, and variety of synthetic polymers, this approach will exclude
the variability's in the drug release imparted by the raw materials
obtained form the natural source. It was my intention to use the simple
aqueous film coating technique to deliver the initial dose for immediate
release and aqueous polymer latex coating to retard the release of second
dose for a period of 5-6 hours.
The rationale for using cellulose polymers for tablet matrix is that
it has been widely used in the formulation of controlled release dosage
forms and also approved by the FDA as 'GRAS' materials. Eudragit was
selected as a retardant film forming material because it was reported in
the literature in various ways to be used in the controlled release dosage
from preparation by coating tablets. forming beads, granulating with
polymer and direct blending of drug polymer and excipients33,34,35,36 .It is
effective in low concentration and is soluble in higher pH which is a
property similar to zein 15. 70.
The purpose of this study was to formulate a modified release
dosage form that would eliminate the use of hazardous organic solvent
coating, also to eliminate the variability in drug release induced by the
raw materials obtained from natural source used for retardant release
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6. To evaluate two different types of processing equipment for their

(

efficiency, reproducibility, and consistency.
7. To perform in-vitro dissolution tests to evaluate the release rate of
albuterol from the marketed product and the developed tablet dosage
form.
8. To compare the dissolution profile obtained from the two different
dissolution apparatus specified in the USP XXII ( Apparatus I and
Apparatus III).

(
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(

m Experimental
1. Materials
A. Chemicals

1. Acetic acid, Glacial Reagent A.S.c.1

2. Acrylic acid copolymer, Rohm Pharma, GmBH, Germany.
3. Ammonium hydroxide solution A.S.c.1
4. Diethyl citrate, Sigma chemical company, St. Louis, Missouri.
5. Hydrochloric acid I
6. Lactose Directly compressible
7. Methanol HPLC grade 1
8. Magnesium stearate, Mallinkrodt Company, New York.
9. Phosphoric acid HPLC grade 1
10. Polyethylene glycol 400, Union Carbide
11. Potassium phosphate di basic 1

12. Sodium hydroxidel

13. Sodium phosphate dibasicl
14. Sodium phosphate monobasicl
15. Sodium acetate!
16. Starch 1500, Colorcon, West Point, Pennsylvania.
1 7. Syloid brand of colloidal silica, Division Chemical, Baltimore,

Maryland.
18. Talc, Amenda Drug and Chemical Co., Irvington, New Jersy.
19. Various cellulose polymers, The Dow Chemical Company,

Midland, Michigan.

1 Fisher Scientific Company, Fair lawn, New Jersy.
(
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(

B. Model drug
Albuterol sulfate (Lot# 180712). Propharmaco, Nobel Industries.

2. Equipment

Accela Cota 24", Thomas Engineering, Hoffman Estates, Illinois.
Bio-Dis Tester, Vankel Industries, Inc., Edision New Jersy.
Carver Laboratory Press, Model C, Fred S. Carver INC., WIS.
Diode Array Spectrophotometer Model 8451 A Hewlett Packard, Atlanta,
Georgia.
Dissolution System, Six spindle basket apparatus, Model 2100, Dis-Teck
Inc., New Jersy.
Electric Balance, Model H8 Mettler, Will Scientific Inc., Rochester, New
York.
Electronic Analytical Balance, Sartorus GmBH, Germany.
Electronic Balance, Mettler, Will Scientific Inc., Rochester, New York.
Fluid Bed Apparatus, Model Strea I, Niro-aeromatic Columbia, Maryland.
Friability Tester, Erweka, GmBH, Germany.
Granule Blender, Turbula Mixer, Switzerland.
Hardness Tester, Digital Model 4M, Schleuniger, Solothurn, Switzerland.
High Speed Disperser, Model 89, Premier Mill Corporation, Reading,
Pennsylvania.
Juliet Particle Size Analyzer, interfaced with image analyzer and Olympus
Optical Microscope Model BHT 232430, Japan.
Peristaltic Pump, Master flex Model 7520-10, Cole Parmer, Chicago,
Illinois.
pH meter, Model 811, Orion Research Inc., Cambridge, Massachusetts.
35

The flow rate was 1.5 ml per minute, the UV detector set at 276 run
(

and the injection volume was 25 µI ( Using WISP). A plot of peak area vs.
concentration was obtained using standard solutions of albuterol sulfate
with concentration ranging from 0-20 µg/ml. The

relationship thus

obtained was linear and used for determining the concentration of
albuterol sulfate in the dissolution sample.
The mobile phase with 70 percent methanol and glacial acetic acid
in deionised, degassed distilled water provided the best resolution and
was used through out these studies. The retention time for albuterol was
found to be 4. 733 minutes. A typical assay chromatogram is shown in
Figure 10. The concentration of albuterol in the sample was calculated by
the following equation.

Concentration of Albuterol (mg/ml)= AUC - 1.480/ 17.487

The amount of albuterol, Xa (mg) was calculated by using the formula
Xa = C 2(239.31/576.70) (ru/rs)

C = Concentration of albuterol in mg/ml
ru =peak response for albuterol in assay preparation
rs = peak response of albuterol in standard preparation.

A linear relationship was observed between the peak area and
albuterol concentration. A standard curve was generated during each
run and the concentration of albuterol in the samples were determined
from the corresponding relationship between peak area and
concentration of standard solution. Figure. 11 shows the calibration
curve for albuterol from 0-20 µg/ml.
37
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Figure 11. HPLC Calibration Curve for Albuterol Sulfate in Deionised water
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Actual percent of albuterol in each formulation was calculated using the

(

following equation
P

= I 00 Xa/ 4 (wt/wa)

wt is the theoretical weight in mg, wa is the actual weight of tablet
composite used for the assay preparation.

3.1.2. UV Detection

Since

the

above

described

High

Performance

Liquid

Chromatography method was time consuming and required only for the
analysis of Proventil tablets. Due to the interference of the tabletting
excipients. The UV spectroscopic method was used for fast and simple
analysis of dissolution samples of the experimental formulations. This
method at a wavelength of 226 nm provided a simple, reliable, and
sensitive assay which was reproducible.

(

For quantitative analysis of albuterol sulfate in the developed
product an ultraviolet (UV) spectrophotometer was used. The resulting
absorbance scan of 8 µg/ ml solution of albuterol sulfate is shown in
Figure.12. From the resulting scan it was evident that albuterol exhibits
2 maximas one at 226 nm and second at 276 nm. The absorbance value
at 226 was greater than that found at 276nm. Hence a shorter
wavelength with higher absorbance value was selected for analysis. A
standard curve for albuterol was obtained at this wave length for
concentrations between 0 to 20 µg/ml. No buffer and excipient
interference was found for

the pH values selected for the in-vitro

dissolution studies. There was no significant difference in absorbance
value measurements. Detection was linear in the range of concentration
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Figure 12. UV Absorbance Scan for Albuterol Sulfate

350

(0-20µg/ml) selected for the calibration curve. The concentration of

(

albuterol was calculated by using the following equation.
Concentration= Absorbance - 0.0073/27.61
A typical standard curve for albuterol is shown in Figure 13. The results
obtained from the two assay methods were compared and the difference
was not significant. Hence the UV assay can be used for routine quality
control measurements for the developed product.

4. Drug Release Studies of Marketed Product

In-vitro drug release from several lots of the marketed product was
studied in various pH mediums in order to mimic the in-vivo dissolution
behavior. The pH's selected were 0.1 N hydrochloric acid pH 1.2, acetate
buffer pH 4 .7. and phosphate buffer pH 7.4 as recommended by USP
XXII. The dissolution study was completed by using two different
dissolution apparatus as specified in the USP XXII as: USP apparatus I
(Basket). and apparatus III (Reciprocating cylinder, Bio-Dis). The
temperature of the dissolution medium was maintained at 37°C ± 0.5oC
in all the studies. The media volume was 500 ml in case of apparatus I
and the basket was rotated at 50 RPM . In apparatus III, 250 ml of
dissolution media was used in each cylinder and the stroke speed was
set to 20 per minute . Samples were collected at specified intervals and
assayed by HPLC to determine the amount of drug released . Sink
conditions were maintained in both methods. UV spectrophotometric
assay was not possible for Proventil-Repetabs due to the interference of
the tablet excipients. Table I. shows the excipients in Proventil-Repetabs
as specified in the labeling.
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Figure 13. UV Calibration Curve for Albuterol Sulfate
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Table I. Ingredients of Proventil Extended Release Tablets•
Albuterol Sulfate 4.8 mg/Tab
Lactose
Acacia
Corn Starch
Carnauba Wax
Butyl Paraben

Calcium Sulfate
Calcium Phosphate
Neutral Soap
White wax
Oleic acid
Rosin
Titanium di oxide
Mg Stearate

Zein

Sucrose
Talc
• As specified in the product label
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5. SCALE UP OF TABLET MANUFACTURE
f

5.1. Laboratory Scale Manufacture

Various formulations of albuterol sulfate tablets were prepared in
the laboratory

by blending the drug. polymer and excipients in a

specified order for a total time of 25 minutes using a turbula
mixture.These blends were compressed using a carver laboratory press
model-C to determine the initial parameters, such as formulation
component concentration, blending time, hardness, tablet weight and
drug release. The initial formulation components of three different
formulations are shown in Table II.
The final formulation selected was scaled up to a batch size of one
kilogram (-7000) tablets using a stokes single punch Fl press with 9/32"
standard concave tooling. The fill volume in the lower punch of the tablet
machine was adjusted to a theoretical weight of 135 mg and the
compression force was adjusted to obtain a tablet hardness of 7-8 kilo
pascals.

5.2. Particle Size Determination
Particle size of the ingredients used in hydrophilic matrix
formulation can have significant impact on the performance and drug
release characteristic56,57. In light of this logic, it was necessary to
determine the particle size of the drug and the excipients used in the
formulation. The particle size was characterized for albuterol sulfate and
all other tabletting excipients used in the study. For this purpose a
Juliet particle size and image

analyzer interfaced with an Olympus

optical microscope under plane polarized light was used. A suspension
containing 5µg/ml of albuterol sulfate in mineral oil was used for

45

(

Table II. Ingredients for Modified Release Albuterol Tablet Cores
Ingredients

%W/W

Albuterol Sulfate
Starch 1500
Lactose DT
Magnesium Stearate
Silicon di oxide
HPMC

1.77
16.74
53.00
0.74
0.74
27.00
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albuterol. Figure 14. shows the particle size distribution histogram for
(

albuterol sulfate. The particle size ranged from 2 to 7 microns with a
mean particle size of 3 microns. About 40 percent of the particles lie in
the range of 2 to 5 microns which is fairly uniform. Figure 15. shows the
particle size distribution histograms for HPMC. A majority of the particles
lie in the size range of 3 to 4.5 microns and complies with the data
reported in the literature28. Figure 16 and 1 7 show the particle size
distribution data for direct compression lactose and starch 1500
respectively. The particle size distribution for lactose ranged from 9 to 14
microns giving an approximate bell shaped distribution. Since the
particle size of all the excipients were fairly uniform. an effective powder
flow and direct compression was possible. Photographs of the particles
were taken using a Polaroid instant photographic camera fitted to the
Olympus optical microscope to study the surface morphology of the
particles. (see figure 18 and 19).

5.3. Blending
Since the blending equipment used in the laboratory was not
applicable for the large scale manufacture it was necessary to redetermine the optimum blending time using the half cubic foot VBlender. In order to optimize the blending time five different lots were
made by varying the total blending time from 30 minutes to 75 minutes.
Drug and excipients were added in specified order similar to ·that of
laboratory scale manufacture, finally magnesium stearate was added as
a lubricant and blended.
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Figure 14. Particle Size Histogram for Albuterol Sulfate
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Figure 18. Albuterol Sulfate Dispersed in Miner:al Oil
Plane Polarized Light (100 X) .

. Figure 19. HPMC Dispersed in Mineral Oil
Plane Polarized Light (100 X)

(
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5.4. Built Density and Flow Properties

The bulk density of all the formulation components, and the
tabletting blend was studied. A weighed amount of powder was placed in
a 100 ml graduated cylinder and the volume occupied by the powder was
determined. A preweighed quantity of powder was placed in a 100 ml
graduated cylinder which was then tapped using a tap density apparatus
(J. Engelsmann A.G. GmBH, Germany) at a constant rate of -500 taps

and the fmal volume was noted as tapped density. These data together
with the initial poured bulk and tapped densities were used to calculate
flowability and the indices of compressibility derived by Hausner (1967)
and Carr (1970)56. The drug excipient blend was placed in a powder
funnel with a one centimeter diameter opening that was supported using
a retard stand such that the bottom of the orifice was 10 centimeters
from the bench surface. The powder was allowed to flow with the help of
(

gravitational force and the angle of repose which is the angle(G) obtained
between the free standing powder heap and the horizontal plane was
measured.

6. PRODUCTION SCALE MANUFACTURE

6.1. Tabletting

The formulation developed in the laboratory was scaled up to a
production size batch of 100,000 tablets. The drug, polymer

and

excipient blend was directly compressed into tablets using 9/32"
standard concave tooling fitted in a Stokes 16 station instrumented
rotary tablet press. The tablet weight and hardness was adjusted to 135
mg and -7 kilo pascals respectively. These tablets were later used for

(

coating. The physical properties of the tablets were studied in accordance
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with the methods specified in the USP XXII. Various parameters such as
(

blending time, powder flow properties, weight variation, hardness and
drug release was determined in an attempt to compare the
reproducibility of the process during large scale manufacture.

7. TABLET COATING

7 .1 Preparation of Seal Coating Suspension
The Eudragit-S was dispersed in distilled water and a specified
concentration of ammonium hydroxide solution was added to the
Eudragit dispersion with constant stirring to effect the partial
neutralization of the polymer55. A dispersion of talc in distilled water was
prepared separately using a high speed dispersator. The talc dispersion
was slowly added to the polymer latex suspension with constant stirring,
plastisizer was added and the latex dispersion was thoroughly mixed.

(

Table III and IV. show the coating solution formulation components for
seal coating and immediate releas.e coating respectively.

7 .2 Preparation of Immediate Release Coating Solution
The coating solution for immediate release portion was prepared as
follows. Hydroxypropylmethyl cellulose was dispersed in distilled water
that had been preheated to 75-SQ<>C. The polymer solution thus formed
was cooled to room temperature and a cold aqueous solution of albuterol
sulfate was added and mixed thoroughly, finally plastisizer was added to
this solution and mixed to obtain a homogeneous coating solution.

(
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Table III. Coating Formula for Retarding Drug Release
Ingredients

%W/W

Eudragit S
Aqueous Ammonia Solution
Triethyl Citrate
Talc
Distilled Water qs

12.00
6 . 10
6 .00
4.00
100.00

Total solids 22 %

55

Table IV. Coating Formula for Immediate Release Portion
Ingredients

%W/W

Albuterol Sulfate

1.54
6.44
2.76
100

HPMC E5M

Polyethylene Glycol 400
Distilled Water Qs
Total solids 10. 7 4%
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7 .3 Coating Procedure
A quantity equivalent to one kilogram (- 7 400 tablets) of tablet
cores was placed in the conical coating vessel of the fluidized bed
apparatus and preheated for 3 minutes at 40°C, the fluidizing air
pressure was set to 10 in a scale of 11. The coating suspension was
sprayed continuously at a rate of 15 grams per minute using a peristaltic
pump.
For the coating applied using the Accela Cota, a quantity
equivalent to seven kilograms of tablet cores(- 51, 000 tablets) was placed
in the pan and preheated for 5 minutes at 40° C, the inlet and outlet
temperatures were maintained at 55 ± 2°C and 35 ± 2°C. The pan was
rotated at a speed of 12 RPM and coating suspension was sprayed
continuously using a peristaltic pump at a rate of 36 grams per minute.
The tablets were further coated with an immediate release portion
containing 2 mg of albuterol per tablet. The tablets were dried for 30
minutes at 400C at the end of the run in both the process.

8. Drug Release Studies for Developed Product
Drug release was studied using USP apparatus I and USP
apparatus III. Six tablets were tested from each lot. The temperature of
the dissolution medium was maintained at 37°C ± 0.5°C in all the
dissolution experiments. For USP apparatus I were withdrawn
automatically at appropriate interval samples with the help of a tris
pump auto sampling unit. The quantity of albuterol dissolved was
determined using a UV spectrophotometer at 226 nm 7. Similarly, the
USP apparatus III was programmed such that the tablets were allowed
to dissolve for a specified time at the specified pH in each row for a total
57

period of twelve hours. At the end of the dissolution period a 5 ml sample
was collected from each dissolution vessel with the help of a glass syringe
fitted with 0 .22 µm membrane filter and samples analyzed in HPLC.
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IV RESULTS AND DISCUSSION

(

This section contains an evaluation of the experimental protocol
and assay techniques used in this study and results thus obtained as
well as a critical discussion and interpretation of these results. This
section is divided into the following sections for easy reference by the
reader.

A. Variability in the Marketed Albuterol Tablets
B. Evaluation of Various Formulations at Laboratory Scale
C. Scale-up of Core Formulation to Full Scale production
D. Evaluation of Coating Manufacturing Methods
E. Dissolution Studies

A. Variability in the Marketed Albuterol Tablets

Various physical characteristics of the Proventil tablets were
studied in an attempt to determine the consistency in tablet weight, and
content uniformity. It can be seen from the results in Table V that lot
RDR-44 has the lowest coefficient of variation for average tablet weight.

The variability in weight may be due to the uneven thickness of sugar
coat which is less consistent than the film coating54,55. The in-vitro
dissolution of these lots of Proventil tablets were studied at various pH's
in order to determine the amount of drug released in the specified time
interval. The results for the two USP apparatus are presented in Table VI
and VII and in Figure 20-21 for USP apparatus I and III respectively. The
results show that the drug release from the tablet core is faster in USP
apparatus III after 5 hours and slower in apparatus I. The faster drug
59

Table V. Content Uniformity and Weight Variation Data for
Several Lots of Proventil Tablets
Lot#
%Albuterol
recovered
Coefficient of
variation
Avg wt
Coefficient of
variation

RDR-244

RDR-44

RDR-254

99.90

102.3

103.5

3.4

3 .9

4 .0

318.77

317.03

319.04

5.0

4.5

6.26

60

----..

Table VI. Dissolution for Various Lots of Proventil Tablets Using USP Apparatus I a
Medium pH

Time (min)

RDR-44

RDR-254

RDR-244

1.2

30

46.65 ± 3.72

53.52 ± 2.81

49.55 ± 3.53

120

47.03 ± 3.07

54.93 ± 2.53

51.71±3.74

210

48.54 ± 4.60

56.41±1.90

55.83 ± 4.91

300

48.54 ± 0.00

58.02 ± 4.11

60.20 ± 5.20

420

63.60 ± 14.46

83.60 ± 7.32

79.13 ± 9.87

600

93.96 ± 10.23

99.11 ± 13.90

98.71±15.32

720

94.28 ± 9.24

105.42 ± 15.52

102.52 ± 10.75

4.7

m
,....

7.4

a values indicate average percent release ± standard deviation (n=6)

Table VII. Dissolution for Various Lots of Proventil Tablets Using USP Apparatus III a
Medium pH

Time (min)

RDR-44

RDR-254

RDR-244

1.2

30

54.58 ± 2.40

50.35 ± 0.90

51.12±4.10

120

55.31±2.53

50.98 ± 1.00

52.44 ± 4.50

240

55.31±2.53

52.50 ± 3.71

55.41±4.50

360

62.34 ± 16.30

77.35 ± 25.17

86.88 ± 22.85

540

107.00 ± 2.92

102.60 ± 2.70

105.59 ± 3.40

720

108.00 ± 2.72

102.95 ± 3. 75

106.95 ± 2. 78

4.7
0)

tv

7.4

a values indicate average percent released ± standard deviation (n=6)

It

----...
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Figure 20. Dissolution for Various Lots of Proventil Tablets USP Apparatus I
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Figure 21. Dissolution for Various lots of Proventil Tablets USP apparatus m
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release may be due to the higher agitation rate in the apparatus IIJ5 3 . A
significant difference in average percent release was observed between
various lots of Proventil tablets independent of the dissolution method
used for testing. Table VIII shows the ANOVA test results for various lots
of Proventil tablets. A significant difference in the mean drug release of
the immediate release portion was observed at 30 minutes and also
difference in mean drug release was observed in the extended release
portion at 360 minutes between RDR-44, RDR-254 and RDR-244. The
variability in the drug release from a coated core tablet can be attributed
to various factors such as coating thickness44,47, solubility of coating
material, diffusion of drug through the coating layer and aging of the
coating material55,56. In this formulation the variability may be due to the
coating thickness and the aging of the retardant coating material.
r

B. Evaluation of Various Formulations at Laboratory Scale
1. Design of Core Tablets

Based upon the above findings, a synthetic polymer with well
defined release characteristics, which is soluble at pH higher than 6.8
was selected to seal coat the core tablets of the experimental formulation.
An aqueous film coating technique was used to coat both core and the

immediate release portion.
In an attempt to match the drug release observed in the extended
release portion of Proventil repetabs, various core formulations were
made by directly compressing powder blends with different proportions of
starch, lactose and hydroxypropylmethylcellulose plus albuterol sulfate
(see Table IX),

65

(

Table VIII. ANOVA Test Results for Average Percent Release at Various
Sampling time for Proventil Tablets a

(

Time (min)

RDR-44

RDR-244

RDR-254

30

+

+

+

360

+

+

+

720
+ indicates a significant difference in the mean percent release between lots

The observed F value is compared to the theoretical Fat a 95% confidence
df = 2 for treatments and 18 for error at all time points
aUSP Apparatus III
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Table IX. Formulation Component Concentrations for 2 mg
Albuterol Tablet Cores
Ingredients

46A

Starch 1500
Lactose DT
HPMC

22.60
67.50
45.00

Lot of Tablet Core (mg)
46B
22.60
71.55
36.45

Each formulation contains Albuterol Sulfate 2.4 mg.
Magnesium stearate and silicon dioxide I mg each.
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46C
13.50
80.65
36.45

to obtain a tablet core that would exibit a near zero order releases for a
(

period of 5 to 6 hours.
The effect of the soluble components on the drug release was
studied to determine the optimum concentration of these excipients
necessary to obtain the desired drug release profile. The dissolution
results obtained from various formulations are shown in Table X and
Figure 22. It can be seen that drug release from formulation 46A with the
highest concentration of hydroxypropylmethylcellulose and a low
concentration of soluble excipients is fastest. Conversely, formulation
46C with a higher concentration of the soluble excipients and lower
concentration of polymer shows slower drug release. Formulation 46B
was found to release about 25 percent in the first 30 minutes followed by
approximately 15 percent every hour with 100 percent of the drug is
released in 5-6 hours.
Therefore, it can be seen that drug release was significantly altered
by varying the concentration of lactose in a formulation containing
hydroxypropylmethycellulose. The formulation containing 48 percent
lactose releases the drug faster and one with 59 percent releases slower.
This difference in release is due to the fact that polymer hydration is
effected by increasing the concentration of soluble excipients57,59.
The physical characteristics of the tablets were evaluated for all the
formulations. The bulk density data in Table XI show that formulation
46B has better consolidation and flow compare to 46A and 46C. Though
formulation 46C has bulk properties similar to that of 46B, it was not
selected because of its slower drug release. The friability of formulation
46B was slightly less (< 0.005 percent) compared to the other two
formulations and the hardness ranged from 7-8 kilopascals. Thus

(
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Table X. Dissolution of Various Core Tablet Formulations Using the USP
Apparatus I a
Time (min)

46A

46B

46C

30

26.05 ± 1.90

26.75 ± 0 .60

23.81±0.63

120

65.50 ± 2.01

55.93 ± 1.10

50.99 ± 0.80

180

82.03 ± 2.00

69.72 ± 1.20

65.08 ± 1.30

240

92.30 ± 2.10

81.21 ± 1.30

77.77 ± 0.70

360

102.10 ± 1.70

98 .01±1.30

92.84±0.90

480

103.10 ± 1.73

102.20 ± 1.50

99.98 ± 1.00

a n=6, values indicate average percent release ± standard deviation.
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Figure 22. Effect of Formulation Component Concentration on
Drug Release Using USP Apparatus I
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Table XI. Bulk Density Data for Various Lot of Core Tablet
Formulation Blends

46A

Lot#
46B

46C

Bulk Density Poured

0 .663

0 .598

0 .614

Bulk Density Tapped

0.819

0.722

0.737

Compressibility

19.01

17.17

16.68

Hausner Ratio

1.23

1.20

1.19

Repose Angle (9)

32°

28°

28°

Bulk Density (gm/ cm3)

(
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formulation 468 was selected as the final formulation for further
(

experiments and scale-up.

2. Evaluation of Physical Characteristics of Core Tablets

Parameters such as weight variation, hardness, thickness and
friability must lie within an acceptable range for the tablets to be useful
in providing the desired drug release and product characteristics. In
addition, since these tablets would be coated for protection and to control
drug release; it is important that the tablets withstand the physical
stress encountered during the coating process39,42,45. Therefore, it is
necessary to evaluate the physical characteristics of randomly selected
tablets cores from each batch. After selecting formulation 468 as the
final formulation a series of tablet lots (100,000 tablets) were made to
evaluate the physical characteristics of these tablets under production
conditions. Table XII shows the results obtained from these lots . The
hardness falls within the expected range of 7 to 8 kpa for all the lots.
Friability was found to be less than 0.005 percent. All of the test batches
passed the official testing for physical characterization of tablets as
described in USP XXII.

C. Scale-up of Core Formulation to Full Scale Production

After selection of 468 as final core formulation for scale-up, a
series of formulations were made while varying the total blending time to
re-determine the optimum blending time needed for the large scale
production. The results obtained for physical characterization and
content uniformity of these formulations are shown in Table XIII. It is
quite evident from the results of physical characterization of tablet that
72

Table XII. Physical Characteristics of Various Lots of Formulation 46 B Tablet Cores

"'-l

VJ

Lot#

Weight (mg)± sd

Thickness(in) ± sd

Hardness (kpa) ± sd

Friability %*

79A

136.2 ± 1.6

0.1366 ± 0.0005

8.35 ± 0.31

0.005

79B

134.9 ± 0.5

0.1374 ± 0.0003

7.83 ± 0.45

0.000

130A

135.2 ± 0.5

0.1367

± 0.0001

7.50

± 0.32

0.003

130B

134.9 ± 0 .7

0.1389

± 0.0001

7.79

± 0.50

0.001

• n=20, 25 RPM for 4 minutes.

Table XIII. Evaluation of Blending Time for Formulation 46 B Using the V-blender a

'I

Lot#
MixTune (min)
Albuterol % Rec
Coeffecient of
variation
Avg wt mg

32A
30
98.99
4.9

32 B
45
99.98
2.5

32 c
55
99.50
1.6

32D
65
100.95
1.9

32 E
75
99.97
1.7

133.8 ± 6.5

134.2 ± 3.4

134.1±2.5

134.0 ± 2.7

134.1 ± 2 .7

Hardness (kpa)

7.20 ± 2.05

8.30 ± 1.34

7.72 ± 1.04

8.5 ± 1.59

8.9 ± 1.61

0.1363 ± 0.0012
0.001

0.1362 ± 0.0013
0.003

~

Thickness (in)
Friability %

0.1394 ± 0.0024 0.1363 ± 0.0012 0.1362 ± 0.0011
2.13
1.5
0.005

a values indicated are average of ten determinations ± standard deviation

the blending time has a significant effect on the content uniformity and

(

weight variation of the tablets. Tablets made with a total blending time of
30 minutes are softer, and friability was greater than 2 percent.
Variability in weight and uniformity in drug content between tablets was
found to be larger with drug release (see Table XIII) faster than the other
lots with increased blending time. By increasing the total blending time
the variability in content uniformity and weight was reduced and
consistent drug release was observed. However. tablets made with a
blending time above 55 minutes showed no significant improvement in
content uniformity or weight variation than those lots with longer
blending times. The frtability of these tablets were less than 0.05 percent
which signifies that they can withstand the physical stress applied
during the coating processes. Thus the optimum blending time was
selected as 55 minutes.
The final large scale production batch was made with a total
blending time of fifty five minutes and a hardness of 7 to 8 kpa. No
significant difference in mean drug release was observed between tablets
made on a laboratory scale and production scale when tested using USP
apparatus I and III. This shows that the formulation and the processing
method developed was reproducible. The dissolution results of the
various formulations produced in the large scale production with a total
blending time of 55 minutes are presented in Table XIV and Figure 23.

D. Evaluation of Coating Methods
Seal Coating
Tables XV and XVI show the weight variation and percent solid
recovery results obtained for various

75

lots of tablet cores coated in

.......

,--

Table XIV. Dissolution for Various Lots of Albuterol Tablet Cores Using USP Apparatus III a

Time (min)

079A

079 B

130A

130 B

60

37.55 ± 0.07

36.12 ± 0.27

35.90 ± 1.00

36.10 ± 0.68

120

56.96 ± 0.29

55.77

± 0.35

54.71±0.56

54.58 ± 0.62

180

72.36 ± 0.50

70.92 ± 0.16

69.50

± 0.21

69.47 ± 0.59

240

83.64 ± 0.37

82.33 ± 0.17

81.00 ± 0.34

80.66 ± 0.40

300

91.09 ± 0.90

89.91±0.31

88.69 ± 0.69

88.38 ± 0.40

360

95.83 ± 0.50

94.26 ± 0.29

93.05 ± 0.85

93.16 ± 1.00

'I
(j)

a Each tablet contains 2 mg of albuterol (n=6) values indicate average
percent release ± standard deviation

Figure 23. Dissolution Profiles for Final Formulation
of Albuterol Core Tablets
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Table XV. Evaluation of Coating Efficiency of the Eudragit-S Coating
Using the Accela-cota
Lot#

Weight (mg)

Coefficient
of variation

Percent solid
coated

Percent
recovered

79A

147.10

1.00

7.60

90.93

79 B

145.78

1.25

8.00

90.62

130A

150.40

1.13

10.90

87.75

130 B

152.70

1.37

12.50

89.35

n= 10 for all determinations

78

(

Table XVI. Evaluation of Coating Efficiency for the Immediate release
Coating Using the Accela-cota
Lot#

Weight (mg)

Coefficient
of variation

Percent solid
coated

Percent
recovered

79A

154.50

1.00

4.80

66.00

798

152.03

1.04

4.30

68.00

130A

159.80

1.50

5.63

61.00

1308

161.50

1.09

5.85

62.00

n= 10 for all determinations

(
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Accela-cota for both the Eudragit-S seal coating and the Immediate

(

release coating. A series of different flow rates were tested and an
optimum flow rate with uniform spray was found to be 36 grams per
minute for the seal coating and 20 grams per minute for the immediate
release coating. A 0.8 mm spray nozzle was used initially for spraying the
seal coating suspension. However, a potential problem of clogging of the
spray nozzle was observed during the coating process. This problem was
eliminated by replacing the 0.8 mm spray nozzle with 1 mm spray nozzle.
It can be seen from the results in Table XV that the average weight of the

tablets coated with the aqueous latex dispersion of Eudragit-S are
uniform and consistent with a small and insignificant coefficient of
variation (1 to 1.5 percent). The low variability in the average tablet
weight between lots is due to the difference in the coating thickness of
the polymer applied for seal coating. In addition Table XVI shows that the
variability in average tablet weight for immediate release coating is also
very small. Since 2 mg of drug is coated onto each tablet, high variability
in the uniformity of coating would have a significant effect on the dose of
drug delivered for immediate release. The efficiency of the coating process
was determined by calculating the percent recovery of the total solids
coated onto the tablet cores. Table XV shows that about 88 to 90 percent
of the solids sprayed were recovered. It has been reported that percent
recovery can be

increased by adjusting

parameters such as air

pressure, spray nozzle size and decreasing the spray to bed distance39,40.
The processing parameters used for applying the seal coat using the
Accela-cota is presented in Table XVII. After these processing parameters
were determined the optimum coating thickness necessary to seal the
core tablets and retard drug release for a period of 4 to 5 hours was
80

(

Table XVII. Processing Parameters for Accela-cota 24" for Seal Coating
and Immediate Release Coating

12RPM

Pan Speed
Pan Charge
Pump
Avg. weight of Tablet
Flow ratet
Inlet Temperature•
Out let Temperature t
Nozzle Opening
Atomizing air pressure
Spray Type
Inlet air opening

9Kg

Peristaltic
134.6 mg
35 gms/min.
53°± 2°C
36°± 2°C
O.Bmm

25 psi
Continuous
7001&

Immediate Release coating
20 grams /min
* 62 ± 2°C
t 42 ± 2°C

*
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determined by coating selected lots of tablet cores with three different
(

concentration of Eudragit-S latex dispersion. Table XVIII and Figure 24.
show the dissolution results for these three different formulations. The
tablets coated with 4 percent polymer releases the second dose earlier
than the 6 and 8 percent level of coating. However, no significant
difference in retarding drug release was observed by increasing the
concentration of polymer from 6 to 8 percent. It is evident from the
results that the retardation of drug release from the extended release
portion can be changed by varying the coating thickness. The results
show that the concentration of polymer required to delay the drug release
from 5-6 hours requires at least a 6 percent of polymer coating.

Immediate Release Coating
The uniformity and consistency of the coating for immediate
release portion is critical. Since only 2 mg of the active drug is coated
over each tablet core, a slight deviation in the applied coating may cause
significant variability in the dose delivered. For this reason many authors
have suggested using air-less atomization for applying low dose coating
solutionsso.s 1 due to minimum loss of coating solids during this type of
spray process. The resultant drug release obtained from tablets coated
using the Accela-cota shows that a uniform coating could be achieved
using air atomized spray coating. It was determined that as low as 2 mg
of active drug per tablet could be delivered consistently. However, if we
compare the percent recovery results obtained for the Eudragit-S seal
coating which is approximately 90 percent followed by the immediate
release coating (68 percent). the efficiency of immediate release coating is

(

low. This may be due to the low concentration of solids in the immediate
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Table XVIII. Dissolution for Various Concentration of Eudragit-S coating a
Concentration of Eudragit-S Coating
pH of medium

Time (min)

4% polymer

6% polymer

8% polymer

1.2

30

49.06 ± 2.52

51.68 ± 2.21

51.47 ± 3.19

120

52.73 ± 1.81

52.00 ± 1.13

51.99± 2.14

240

64.33 ± 1.93

52.00± 0.00

51.99± 0.00

360

79.37 ± 1.40

52.00 ± 0.00

51.99± 0.00

540

101.49 ± 1.82

82.62 ± 2.23

82.11±1.08

720

103.89 ± 1. 70

100.69 ± 1.56

99.01±2.63

4.7
00

~

7.4

a Equipment - Accela-cota, values represent average percent release
± standard deviation (n=6)

----.
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Figure 24. Effect of Various Concentrations of Eudragit-S Coating on
Drug Release Using USP Apparatus m
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release coating solution. The literature suggests that the percent recovery
f

may be increased by adding inert solids to the coating solution and by
reducing the atomization air pressures 1.s2. This approach seems
reasonable and was tried in fluidized bed coating which is discussed
below. The Accela-cota was not tested for this process due to time
constraints
The results obtained from coating tablets using the fluidized bed
coating apparatus (Aeromatic STREA I) for Eudragit-S seal coat and
immediate release portion are presented in Table XIX and XX
respectively. While literature generally considers the fluidized coating
process to be efficient and consistent in coating granules and tablets41.42,
our results and observations show that this equipment is less efficient
than Accela-cota in providing a uniform coating for tablets. The
coefficient of variation of the average tablet weight for immediate release
coating using fluidized bed coating was high (2 to 3 percent) compare to
the Accela-cota (1 to 1.5 percent). The efficiency of immediate release
coating was also found to be poor using fluid bed process with only about
45 percent of the solids recovered and the processing time extending to
twice that of the Accela-cota. Addition of three percent talc to the coating
solution increased the percent recovery to approximately 75 percent.
However, further studies on improving the coating efficiency were not
conducted due to time constraints. Hence it was not possible to evaluate
this process completely. The optimum coating parameters for the
Aeromatic STREA I is shown in Table XXI.
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Table XIX. Coating Efficiency ot the Eudragit-S Coating Using the
Aeromatic Apparatus
Lot#

Weight (mg)

Coefficient
of variation

Percent solid
coated

Percent
recovered

46A

151.50

1.32

7.80

91.59

46B

150.88

3.04

7.41

90.38

46C

152.70

2.00

7 .56

89.92

n= 10 for all determinations

(
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Table XX. Evaluation of Coating Efficiency for the Immediate Release
Coating Using the Aero matic Apparatus
Lot#

Weight (mg)

Coefficient
of variation

Percent solid
coated

Percent
recovered

46A

165.90

2.27

10.16

46.15

46B

162.29

2.26

9.46

45.13

46C

167. 13

2.77

9.79

74.02

n= 10 for all determinations
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Table XXL Processing Parameters for Fluidized Bed Coating
(Aeromatic STREA I)
Peristaltic
25 grams/min

Pump
Spray rate*
Quantity Coated
Wurster size
Atomizing air
Drying Temperature•
Outlet Temperature t
Nozzle Opening
Spray method
Bottom Plate Opening
Fan Speed
Exhaust
Blow back Pressure
Blow back cycle

1 Kg

9 inch
27 psi
50°C
35°c
lmm

Continuous
4%

11 in a 11 scale
1000/o
15 Psi
15 sec

Processing Conditions for Immediate Release Coating
* 15 grams/ min
* 60° ± 1°C
t 40° ± 1°C

(
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E. Dissolution Studies
(

The Accela-cota was used to apply the seal coat and the immediate
release coating. Tables XXII-XXIII and Figure 25 show the dissolution
results for the final coated formulations as determined using USP
apparatus I and III respectively. Since the total drug concentration was
well below the saturation solubility, it was possible to maintain sink
conditions for both of the dissolution apparatuses. The number of
sampling intervals were limited in case of USP apparatus III due to the
limited capacity of that instrument. The drug release is uniform and
consistent for all the experimental formulations tested in both of the
dissolution apparatuses. While drug release was slightly faster in USP
apparatus III than that found in apparatus I, the difference was not
significant at P<0.05 level. Interestingly, data presented earlier in this
thesis showed significant differences in the mean percent released
between various lots of Proventil tablets using USP apparatus I and III
(see Figure 20-21).
The in-vitro drug release of the marketed product is highly
variable, this in tum may be expected to have a significant effect on the
in-vivo bioavailability. The drug release from the experimental tablets
was found to be consistent with rapid release of the initial 2 mg of drug
followed by a near zero order release of the second dose of 2 mg for
period of 5-6 hours that was seen for the Proventil tablets. This second
interval of drug release indicates that a steady state plasma level should
be maintained. While the in-vitro drug release profiles of the
experimental tablets are comparable to the marketed product and exhibit
significantly less variability in drug release further clinical investigation
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Table XXII. Dissolution of Albuterol Tablets Using USP Apparatus I a
Experimental Lots
pH of
medium
1.2

4.7

co
0

7.4

Time
(minutes)

79A

79B

130A

1308

30

49.8 ± 2.00

49.45 ± 1.90

46.59 ± 3.71

46.30 ± 2.70

120

52.7 ± 2.00

49.76 ± 1.90

49.42 ± 2.16

47. 01±2.15

180

53.8 ± 1.53

49.76 ± 1.90

49.42 ± 0.16

47. 01±2.15

240

60.7 ± 1.72

49.76 ± 1.90

49.42 ± 0.16

47. 01±2.15

300

74.0 ± 2.07

64.42 ± 2.01

63.07 ± 2.25

63.05 ± 1.87

480

84.9

± 2.59

72.59 ± 1.13

71.45 ± 1.17

70.57

± 1.35

600

91.8

± 2.01

90. 86 ± 1.02

88.32 ± 2.25

86.13

± 2.30

97.0 ± 1.5

103.36 ± 1.5

94.48 ± 2.50

92.93 ± 1.97

720

a Average percent release of six tablets ± standard deviation

---...

Table XXIII. Dissolution of Albuterol Tablets Using USP Apparatus III a
Experimental Lots

Time

CD

pH of medium

(min)

79A

79B

130A

130 B

1.2

30

47.71 ± 1.38

51.26 ± 2.00

51.09 ± 3.71

51.48 ± 3.72

120

51.42 ± 2.05

51.26 ± 2.00

51.10 ± 4.00

52.00 ± 3.76

210

62.72 ± 3.65

51.26 ± 2.00

51.10 ± 0.00

52.00 ± 0.76

300

77.38 ± 4.45

51.26 ± 2.00

51.10 ± 0.00

52.00 ± 0.76

510

98.96 ± 2.18

84.12 ± 1.53

80. 32 ± 2.72

82.13 ± 2.50

720

101.68 ± 2.08

100.00 ± 1.32

98.40 ± 1.53

98.75 ± 1.71

4.7

......

7.4

a Average percent release of six tablets ± standard deviation

_,,.,.

Figure 25. Comparision of Dissolution Profiles for Different
Lots of Albuterol Tablets Using USP Apparatus I and m
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of the in-vivo drug release are needed before a fmal comparision of
(

bioequivalence can be determined.
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V CONCLUSIONS

(

1. In-vitro dissolution studies of the marketed repeat-action product

showed significant differences in mean drug release between various
lots.

2. A sensitive, reliable and reproducible lN assay method was developed
for quantitation of albuterol. Comparison of this lN method to a stability
indicating HPLC assay method shows both assays to be equivalent for
the experimental formulations and allowed use of the less labor intensive
lN method throughout this study.

3. A core tablet formulation was

developed in the laboratory and

successfully scaled-up to the production size batch level. The optimum
blending time to prepare uniform distribution of drug and weight for
large scale production was determined. Optimum concentrations of the
tablet excipients necessary to obtain the desired drug release profile were
determined.

4. The optimum concentration of a safe aqueous solvated polymer which
provided a seal coating and retarded drug release for a period of 5 to 6
hours was determined.

5. The optimum coating parameters for the immediate release coating
using an aqueous polymer solution was determined. Two different
manufacturing methods, the Accela-cota and the Areomatic fluid bed
coating, were compared and their
(

coating efficiency evaluated. The

Accela-cota was found to be more efficient than the fluid bed coating
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process for applying the immediate release portion. However, the seal
(

coat can be applied either of the two apparatus, But the Accela-cota is
preferred due to its larger production capacity.

6 . The dissolution profiles obtained for the experimental formulations
using the USP apparatuses I and III were found to be comparable. The
drug release profiles for the experimental formulations were not
significantly affected by the different dissolution methods and found to
be uniform, consistent and reproducible .
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·~ \ 1ty supervisor SUMMER 2014: Yan Ma, URI GSLIS, Rodman Hall 106, yanma@uri.edu

r;

' ~~---~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

l
~l it hotirs: J_ Hours on site (45 per credit): 90 hours Start date: 5/5/14 End date: 7/25/ l 4
I

_L;ise dtscription (e .g ., "Chi ldren 's library service" or "Cataloging special collection or "Reference and
or Digital Specialist, etc.): Digital Initiatives: Archival file and audiovisual data
iervation strategies, copyright and open access policy research, repository management for
lj
RI oigital Commons
~ ·· uctioil"

1\

'"'l or objectives. Placement will emphasize GSLIS Educational Outcome 1, Professional Ethics, and
"<,11leen 0 1w and three other outcomes as appropriate; see attached page for list. Example. for a PFE in
~~J' fogin&{• a major objective would be based on Educational Outcome 3, "Knowledge Organization. "
11( se mdke your objectives specific to your placement objectives but based on GSLIS outcomes.
· fessionalEthics: Respect intellectual property rights and advocate balance between the
t.( rests of information users and rights holders (ALA Code of Eth ics )
: Jnderstand the evolution of different types of library and information services in response
'· hang;ng technologies and community needs.
i .' \:3e all"'are of the legal framework within which libraries and information agencies operate,
E 1 the certification and/or licensure requirements of professional specialties.
~ \Apply' knowledge of concepts, issues, and methods of collection management flexibly to the
~~·1 1l uation, accession, storing, preserving, conserving, disseminating of information in all media.
f'l,' ific 3 ctivities to be carried out in support of objectives. Student practice will support the major
! u~ ctives· For instance, a children's services placement might support Outcome 5 through reference and
• ' Vers' ddvisory work in children 's room; an archival placement might support Outcome 3 through
1
1
~ •loprne nt of a finding aid and for reference and instruction Outcomes 5 & 7.
1 .tbem"nstrate understanding of the principles involved in the organization and
> • ·esentation of recorded knowledge and information
' Can ~pply technologies consistently with professional ethics and prevailing service norms
l\pply the principles and methods used to assess the value of new research.

